Infinity Pharmaceuticals | INFI - Interest Expense On Debt


Infinity Pharmaceuticals reported $45K in Interest Expense on Debt for its fiscal quarter ending in June of 2023.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Cipla INR 140.3M 8.5M Dec/2025
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Incyte USD 582K 10K Dec/2025
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Ionis Pharmaceuticals USD 18M 0 Dec/2025
J&J USD 18M 290M Sep/2025
Novartis USD 304M 23M Dec/2025
Pfizer USD 711M 59M Dec/2025
Plus Therapeutics USD 62K 25K Dec/2023
Roche Holding CHF 304M 7.5M Jun/2025
TG Therapeutics USD 6.53M 187K Dec/2025